当前位置： SCI文献检索 > CLINICAL THERAPEUTICS期刊下所有文献 > Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.

Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.

Abstract：

:The pharmacodynamic parameter that appears to correlate best with a successful therapeutic outcome with beta-lactam antibiotics is the length of time the serum antibiotic concentration remains above the minimum inhibitory concentration (MIC) for the infecting pathogen. By maximizing this parameter, continuous administration of beta-lactam and related antibiotics by intravenous infusion could represent the optimal mode of drug administration. The pharmacokinetic and pharmacodynamic properties of ceftazidime administered by continuous intravenous infusion have been evaluated previously. Aztreonam is a monobactam antibiotic with similar pharmacokinetic and microbiologic activity to that of ceftazidime. This study evaluated the pharmacokinetic and pharmacodynamic characteristics of aztreonam administered as a continuous intravenous infusion in healthy volunteers against multiple clinical isolates. Five men and 3 women received 6 g of aztreonam administered by continuous intravenous infusion over 24 hours. Blood samples were collected before the infusion and at 0.5, 1 through 8, 12, 18, and 24 hours after the start of the infusion. Pharmacokinetic parameters were determined by standard equations. In vitro susceptibility testing was performed using National Committee for Clinical Laboratory Standards guidelines for 4 clinical isolates of gram-negative bacteria (2 each of Escherichia coli and Pseudomonas aeruginosa). Serum inhibitory titers (SITs) were determined in duplicate for each clinical isolate at 0 and 24 hours. The subjects' mean (+/- SD) age was 29.3+/-4.4 years; mean weight, 74.6+/-14.0 kg; and calculated mean creatinine clearance, 107+/-13 mL/min. For the pharmacokinetic parameters, mean (+/- SD) values were as follows: steady-state serum concentration, 40.9+/-8.8 microg/L; half-life, 1.5+/-0.4 hours; elimination rate constant, 0.50+/-0.13 hours(-1); steady-state volume of distribution, 0.18+/-0.04 L/kg; and total body clearance, 6.1+/-1.2 L/h. The MICs were 0.0625 and 0.125 microg/mL against the 2 E coli isolates and 4 microg/mL against both P aeruginosa isolates. The median SITs against the E. coli isolates were 1:256 and 1:512, and against the P. aeruginosa isolates were 1:8 and 1:16. At steady state, II subjects had serum concentrations of aztreonam > or =4 times the MIC for each organism. These findings suggest that further clinical study of the administration of aztreonam by continuous intravenous infusion is warranted.

journal_name

Clin Ther

journal_title

Clinical therapeutics

authors

Burgess DS,Summers KK,Hardin TC

doi

10.1016/S0149-2918(00)86736-3

subject

Has Abstract

pub_date

1999-11-01 00:00:00

pages

1882-9

issue

11

eissn

0149-2918

issn

1879-114X

pii

S0149-2918(00)86736-3

journal_volume

21

pub_type

杂志文章

相关文献

CLINICAL THERAPEUTICS文献大全
  • Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen.

    abstract：BACKGROUND:In patients with type 2 diabetes, published data suggest that glycemic control can be achieved as effectively with an inhaled insulin regimen (preprandial inhaled intrapulmonary insulin plus a single bedtime Ultralente injection) as with a conventional subcutaneous insulin regimen involving 2 to 3 injections...

    journal_title：Clinical therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/s0149-2918(02)85131-1

    authors： Cappelleri JC,Cefalu WT,Rosenstock J,Kourides IA,Gerber RA

    更新日期：2002-04-01 00:00:00

  • Chromatographically purified vancomycin: therapy of serious infections caused by Staphylococcus aureus and other gram-positive bacteria.

    abstract：:Fourteen patients with serious infections caused by Staphylococcus aureus and other gram-positive bacteria were prospectively treated with chromatographically purified vancomycin in an open-label, nonrandomized study, between December 1986 and June 1987. Five patients were excluded from the evaluation of efficacy. Amo...

    journal_title：Clinical therapeutics

    pub_type： 临床试验,杂志文章

    doi：

    authors： Wang LS,Liu CY,Wang FD,Fung CP,Chiu ZH,Cheng DL

    更新日期：1988-01-01 00:00:00

  • Enoxacin in the treatment of typhoid fever.

    abstract：:Enoxacin 400 mg twice daily was given orally to 40 patients who had Salmonella typhi- or Salmonella paratyphi-positive blood or bone marrow cultures. One patient was switched to parenteral therapy within 48 hours of study enrollment, but the remaining 39 patients were given enoxacin for 10 to 14 days. All 39 patients ...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：

    authors： Ahmed A,Salahuddin N,Ahsan T,Afsar S,Nasir N,Farooqui S,Chaoudri AN,Akhtar MA,Agha I,Nagi N

    更新日期：1992-11-01 00:00:00

  • Solving the antidepressant efficacy question: effect sizes in major depressive disorder.

    abstract：BACKGROUND:Numerous reviews and meta-analyses of the antidepressant literature in major depressive disorders (MDD), both acute and maintenance, have been published, some claiming that antidepressants are mostly ineffective and others that they are mostly effective, in either acute or maintenance treatment. OBJECTIVE:T...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,评审

    doi：10.1016/j.clinthera.2011.11.019

    authors： Vöhringer PA,Ghaemi SN

    更新日期：2011-12-01 00:00:00

  • Open-label, dose-ranging pilot study of 4 weeks of low-dose therapy with sodium phosphate tablets in chronically constipated adults.

    abstract：BACKGROUND:The tablet formulation of sodium phosphate (NaP) is a prescription osmotic purgative that has been marketed since 2001. The use of NaP tablets in patients with constipation has not been studied previously. OBJECTIVE:This study assessed the tolerability and efficacy of 28 days of therapy with NaP tablets (1....

    journal_title：Clinical therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/j.clinthera.2004.09.007

    authors： Medoff J,Katz S,Malik P,Pambianco D,Pruitt R,Poulos J,Rank J,Rose M

    更新日期：2004-09-01 00:00:00

  • Safety of bronchodilator therapy in pediatric asthma patients.

    abstract：:This article reviews the drugs used in the treatment of childhood asthma (bronchodilators and anti-inflammatory agents) from the perspective of their safety and clinical tolerability. Adverse events observed in adults are likely to be seen to a greater degree in children and adolescents for many types of antiasthma dr...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,评审

    doi：

    authors： Selcow JE

    更新日期：1994-07-01 00:00:00

  • Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension.

    abstract：BACKGROUND:A sprinkle capsule formulation containing enteric-coated, delayed-release rabeprazole granules is being developed for the treatment of children with gastrointestinal reflux disease. The granules are designed to be mixed with vehicles that facilitate delivery to children, who may be unable to swallow solid fo...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.clinthera.2012.06.008

    authors： Thyssen A,Solanki B,Treem W

    更新日期：2012-07-01 00:00:00

  • Cefoperazone therapy of serious infections.

    abstract：:Cefoperazone was evaluated as the therapeutic agent in 64 adults with serious infections. Included were pneumonias, urinary tract infections, septicemia, osteomyelitis, joint infections, and superficial infections. A total of 84 organisms, including many multiantibiotic-resistant strains, were designated as the etiolo...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：

    authors： Temple J,Mogabgab WJ

    更新日期：1982-01-01 00:00:00

  • Current attitudes on cardiac devices in heart failure: a review.

    abstract：PURPOSE:Despite significant advances in optimizing drug therapy, heart failure-related mortality and morbidity remain high. There has been great progression with regard to device therapy in heart failure, and device use continues to increase. The aims of this review were to critically re-examine the evidence base and t...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,评审

    doi：10.1016/j.clinthera.2015.08.012

    authors： Marangou J,Paul V

    更新日期：2015-10-01 00:00:00

  • A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.

    abstract：OBJECTIVE:The aim of this study was to test the ability of human insulin 70/30, insulin lispro mixture 75/25 (75% neutral protamine lispro [NPL], 25% insulin lispro), and insulin lispro mixture 50/50 (50% NPL, 50% insulin lispro) to control postprandial glucose (PPG) concentrations in patients with type 2 diabetes mell...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.clinthera.2006.10.017

    authors： Schwartz S,Zagar AJ,Althouse SK,Pinaire JA,Holcombe JH

    更新日期：2006-10-01 00:00:00

  • Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases.

    abstract：PURPOSE:Our study evaluated adverse events of therapeutic failure (and specifically reduced duration of action) with the use of a branded product, Osmotic Release Oral System (OROS) methylphenidate, which is approved for the treatment of attention deficit/hyperactivity disorder, and a generic product (methylphenidate, ...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2017.08.018

    authors： Park-Wyllie L,van Stralen J,Castillon G,Sherman SE,Almagor D

    更新日期：2017-10-01 00:00:00

  • Patient adherence to prescribed potassium supplement therapy.

    abstract：:We have investigated whether patient adherence ratios calculated from prescription refill data for potassium supplement medications differ depending on the type of supplement. By using automated pharmacy claims records from a large managed care organization, an index of adherence to prescribed therapy was calculated f...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：

    authors： Halpern MT,Irwin DE,Brown RE,Clouse J,Hatziandreu EJ

    更新日期：1993-11-01 00:00:00

  • Endoscopic comparison of three aspirin preparations and placebo.

    abstract：:Eighty of 84 volunteers aged 22 to 70 years successfully completed a 3-month, single-blind endoscopic study in which they received single-dose placebo or 325 mg/day of enteric-coated aspirin (ECA), buffered aspirin (BA), or plain aspirin (ASA). Upper endoscopy was performed at the beginning of the study and after 4, 8...

    journal_title：Clinical therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：

    authors： Petroski D

    更新日期：1993-03-01 00:00:00

  • Tolerability of antihypertensive drugs in a community-based setting.

    abstract：BACKGROUND:Outside the experimental environment of clinical trials, the tolerability of angiotensin-converting enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), and the angiotensin II antagonist losartan has not been compared. OBJECTIVES:The purpose of this study was to estimate, in current clinical practice...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/s0149-2918(01)80021-7

    authors： Grégoire JP,Moisan J,Guibert R,Ciampi A,Milot A,Côté I,Gaudet M

    更新日期：2001-05-01 00:00:00

  • Effects of felodipine on natriuresis, atrial natriuretic factor, the renin-angiotensin-aldosterone system, and blood pressure in essential hypertension.

    abstract：:The aim of this study was to evaluate the short-term and long-term effects of felodipine, a new dihydropiridine calcium antagonist, on arterial blood pressure (BP), the renin-angiotensin-aldosterone system, diuresis, natriuresis, and the atrial natriuretic factor (ANF). In 15 essential hypertensives (WHO class II) BP,...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：

    authors： Cerasola G,Cottone S,Mangano MT,D'Ignoto G,Pinto A,Carone MB

    更新日期：1988-01-01 00:00:00

  • Lessons learned with ambulatory blood pressure monitoring: a focus on ramipril.

    abstract：:Ambulatory blood pressure monitoring (ABPM) has been available since the mid-1970s. Widespread use of ABPM in research settings has led to an appreciation of its advantages and disadvantages. ABPM is a valuable research tool because of its ability to evaluate the duration and consistency of action with new antihyperte...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,评审

    doi：

    authors： Burris JF

    更新日期：1993-05-01 00:00:00

  • Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?

    abstract：PURPOSE:Although recent reports suggest an association between saxagliptin and an increased risk of admissions for heart failure, it is not clear whether dipeptidyl peptidase IV (DPP-IV) inhibition contributes to heart failure in high-risk patients. The purpose of this research is to understand heart failure risk among...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,评审

    doi：10.1016/j.clinthera.2014.10.009

    authors： Clifton P

    更新日期：2014-12-01 00:00:00

  • Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.

    abstract：BACKGROUND:Gastrointestinal (GI) symptoms and high dosing frequency have been cited as reasons for inadequate adherence to daily or weekly oral bisphosphonate therapy. Inadequate adherence may lead to poor therapeutic outcomes. OBJECTIVE:The PRIOR study evaluated adherence to and GI tolerability of monthly therapy wit...

    journal_title：Clinical therapeutics

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/j.clinthera.2008.04.009

    authors： Lewiecki EM,Babbitt AM,Piziak VK,Ozturk ZE,Bone HG

    更新日期：2008-04-01 00:00:00

  • The efficacy of two doses of omeprazole for short- and long-term peptic ulcer treatment in the elderly.

    abstract：:This study evaluated the efficacy, safety, and most suitable dose of omeprazole in short-term acute treatment (4 weeks) and maintenance treatment (6 months) of patients older than 60 years of age with endoscopically diagnosed gastric ulcer (GU) or duodenal ulcer (DU). This randomized, prospective study included 156 pa...

    journal_title：Clinical therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：

    authors： Pilotto A,Di Mario F,Battaglia G,Vigneri S,Leandro G,Franceschi M,De Boni M,Grasso A,Vianello F,Naccarato R

    更新日期：1994-11-01 00:00:00

  • Analysis of prescription pattern and guideline adherence in the management of asthma among medical institutions and physician specialties in Taiwan between 2000 and 2010.

    abstract：PURPOSE:The aim of this study was to evaluate prescription patterns of antiasthmatic medications in ambulatory care, guideline adherence by physician specialties and medical institutions, and the rate of hospitalization and emergency department visits due to asthma exacerbation. METHODS:The ambulatory visits between 2...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2015.07.024

    authors： Chou CL,Perng DW,Lin TL,Lin AM,Chen TJ,Wu MS,Chou YC

    更新日期：2015-10-01 00:00:00

  • Why Are We Still Creating Individual Case Safety Reports?

    abstract：:The history of drug safety monitoring, or pharmacovigilance, has been an interesting one. Despite many and ongoing changes, it has typically been characterized by a rather slow-moving and reactive progression. Pharmacovigilance has always lagged behind other fields and industries and has been slow to adapt to new appr...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2018.10.012

    authors： Streefland MB

    更新日期：2018-12-01 00:00:00

  • Cost of Bleeding-related Episodes in Adult Patients With Primary Immune Thrombocytopenia: A Population-based Retrospective Cohort Study of Administrative Claims Data for Commercial Payers in the United States.

    abstract：PURPOSE:We estimated the real-world costs of bleeding-related episodes (BREs) in adults with primary immune thrombocytopenia (ITP). METHODS:This retrospective cohort study used the MarketScan Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits databases. We identified adult patients...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2017.01.023

    authors： Lin J,Zhang X,Li X,Chandler D,Altomare I,Wasser JS,Cetin K

    更新日期：2017-03-01 00:00:00

  • Review of Interventions for the Frailty Syndrome and the Role of Metformin as a Potential Pharmacologic Agent for Frailty Prevention.

    abstract：PURPOSE:Frailty is a syndrome of vulnerability and physical decline with aging that increases risk for disability, hospitalizations, and death. To date, interventions for frailty have primarily focused on exercise and/or nutritional interventions, many of which show improvement in frailty-related characteristics, such ...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,评审

    doi：10.1016/j.clinthera.2019.01.006

    authors： Espinoza SE,Jiwani R,Wang J,Wang CP

    更新日期：2019-03-01 00:00:00

  • Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group tri

    abstract：BACKGROUND:Combination therapy with at least 2 antihypertensive agents is usually needed to achieve appropriate blood pressure (BP) control in patients with isolated or predominant systolic hypertension. A currently recommended combination is a diuretic added to an angiotensin-receptor blocker. OBJECTIVE:This was a st...

    journal_title：Clinical therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.clinthera.2005.07.010

    authors： Lacourcière Y,Poirier L,Hebert D,Assouline L,Stolt P,Rehel B,Khder Y

    更新日期：2005-07-01 00:00:00

  • Comparison of hydrochlorothiazide and hydrochlorothiazide plus bevantolol in hypertension.

    abstract：:The added hypotensive effect of bevantolol, a new cardioselective beta-blocker, was studied in 244 patients with mild to moderate essential hypertension following prior treatment with hydrochlorothiazide or placebo. After four weeks of monotherapy with 50 mg/day or 100 mg/day of hydrochlorothiazide or placebo, the mea...

    journal_title：Clinical therapeutics

    pub_type： 临床试验,杂志文章

    doi：

    authors： Lucas CP,Morledge JH,Tessman DK

    更新日期：1985-01-01 00:00:00

  • Overview of US Maternal Mortality Policy.

    abstract：:The United States maternal mortality rate has been rising for many years putting the US out of step with peer countries. There are many complex reasons for the rise in maternal deaths and recent data has demonstrated that there is a disproportionate risk for women of color. This article provides an overview of current...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,评审

    doi：10.1016/j.clinthera.2020.01.015

    authors： Villavicencio JC,McHugh KW,Edmonds BT

    更新日期：2020-03-01 00:00:00

  • Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propiona

    abstract：BACKGROUND:The use of dry-powder inhalers (DPIs) to administer respiratory medicines is increasing, and new DPIs are likely to be developed because of expiring patents. However, there is considerable debate concerning the extent to which DPIs are interchangeable without altering disease control or the safety profile of...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2009.02.007

    authors： Daley-Yates PT,Parkins DA,Thomas MJ,Gillett B,House KW,Ortega HG

    更新日期：2009-02-01 00:00:00

  • Human leukocyte interferon in the treatment of rheumatoid arthritis.

    abstract：:Forty patients with symptoms of rheumatoid arthritis were treated with daily injections of 100 micrograms of human leukocyte interferon or saline placebo. Twenty patients received the interferon for nine weeks and were then switched to placebo for nine weeks, and 20 patients were started on placebo and were then switc...

    journal_title：Clinical therapeutics

    pub_type： 临床试验,杂志文章

    doi：

    authors： Peddinani MV,Savery F,Hang LM

    更新日期：1986-01-01 00:00:00

  • Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapy.

    abstract：BACKGROUND:Clinical trials have shown that treatment with disease-modifying therapies (DMTs), such as interferon, at the time of clinically isolated syndrome can delay the onset of multiple sclerosis (MS). OBJECTIVES:The objective of this study was to assess health care utilization and expenditures associated with tre...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2011.05.049

    authors： Curkendall SM,Wang C,Johnson BH,Cao Z,Preblick R,Torres AM,Knappertz V,Gondek K

    更新日期：2011-07-01 00:00:00

  • Echinacea in the prevention of induced rhinovirus colds: a meta-analysis.

    abstract：BACKGROUND:The therapeutic effectiveness of Echinacea in the treatment and the prevention of colds has been debated. Studies of naturally occurring colds are hampered by variability in time from onset of symptoms to treatment and by heterogeneity in trial design. Experimental infection studies allow for the standardiza...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,meta分析,评审

    doi：10.1016/j.clinthera.2006.02.001

    authors： Schoop R,Klein P,Suter A,Johnston SL

    更新日期：2006-02-01 00:00:00